ERBB2 and cancer: As the most frequently identified ER in 26 cancers (Figure S1A), TP53 mutation was involved in the ERBB signalling and ligand–receptor pairs correlated with chemokines, e.g. L1CAM‐ERBB2 and CCL8‐CCR3 (Figure 1C).